Download File - JOHN J. HADDAD, Ph.D.

66 Srinivasan
33. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor
cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments
antitumor immunity in some patients with metastatic non-small-cell lung
carcinoma. J Clin Oncol 2003; 21(4):624–630.
34. Maio M, Fonsatti E, Lamaj E, et al. Vaccination of stage IV patients with allogeneic
IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies
against vaccinating and autologous melanoma cells. Cancer Immunol Immunother
2002; 51(1):9–14.
35. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response
to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;
19(18):3836–3847.
36. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells
engineered to secrete murine granulocyte-macrophage colony-stimulating factor
stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci
USA 1993; 90(8):3539–3543.
37. Bowne WB, Wolchok JD, Hawkins WG, et al. Injection of DNA encoding granulocyte-macrophage
colony-stimulating factor recruits dendritic cells for immune
adjuvant effects. Cytokines Cell Mol Ther 1999; 5(4):217–225.
38. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and
paclitaxel enhance the antitumor immune response of granulocyte/macrophagecolony
stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized
mice. Cancer Res 2001; 61(9):3689–3697.
39. Borrello I, Sotomayor EM, Rattis FM, et al. Sustaining the graft-versus-tumor effect
through posttransplant immunization with granulocyte-macrophage colonystimulating
factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95(10):
3011–3019.
40. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, et al. Gene immunotherapy in
murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor
tumor cell vaccines elicit more potent antitumor immunity compared with B7 family
and other cytokine vaccines. Blood 1998; 91(1):222–230.
41. Cell Genesys, Inc. Available at: http://www.cellgenesys.com/clinical-stage.shtml.
Accessed 2005.
42. Cervarix. Cervarix is approved in Australia for females 10–45 years old. GSK, 2007.
43. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a
bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and
18: follow-up from a randomised control trial. Lancet 2006; 367(9518):1247–1255.
44. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary
cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1):12–19.
45. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application.
Nat Rev Cancer 2002; 2(5):342–350.
46. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different
human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm.
J Virol 1991; 65(2):606–612.
47. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and
18 gene expression in cervical neoplasias. Hum Pathol 1992; 23(2):117–128.
48. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16
virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal
and systemic neutralizing antibodies in mice. Infect Immun 1997; 65(8):3328–3336.